Natixis Nevro Corp Transaction History

Natixis

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$18.22 - $25.85 $136,650 - $193,875	7,500 Added 27.78%	34,500 $663,000
Q2 2023 Aug 11, 2023	BUY	$22.62 - $39.32 $514,605 - $894,530	22,750 Added 535.29%	27,000 $686,000
Q1 2023 May 12, 2023	BUY	$30.17 - $41.11 $128,222 - $174,717	4,250 New	4,250 $153,000
Q1 2022 May 13, 2022	SELL	$59.95 - $92.06 $2.03 Million - $3.12 Million	-33,900 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$81.07 - $121.29 $405,349 - $606,450	5,000 Added 17.3%	33,900 $2.75 Million
Q3 2021 Nov 12, 2021	SELL	$101.99 - $166.36 $4.69 Million - $7.65 Million	-46,000 Reduced 61.42%	28,900 $3.36 Million
Q2 2021 Aug 13, 2021	BUY	$141.6 - $179.06 $10.6 Million - $13.4 Million	74,900 New	74,900 $12.4 Million
Q1 2021 May 14, 2021	SELL	$132.81 - $182.18 $1.83 Million - $2.51 Million	-13,800 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$138.17 - $184.34 $1.91 Million - $2.54 Million	13,800 New	13,800 $2.39 Million
Q4 2017 Feb 14, 2018	SELL	$65.94 - $93.31 $227,031 - $321,266	-3,443 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$80.87 - $91.08 $278,435 - $313,588	3,443	3,443 $313,000

151

39.3M

67.9K

1.59M

Ticker NVRO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 35,387,800
Market Cap $133M
Description
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.